X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with Divis Laboratories - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs DIVIS LABORATORIES - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH DIVIS LABORATORIES PANACEA BIOTECH/
DIVIS LABORATORIES
 
P/E (TTM) x 137.7 31.3 439.7% View Chart
P/BV x 3.1 5.4 56.4% View Chart
Dividend Yield % 0.0 0.9 -  

Financials

 PANACEA BIOTECH   DIVIS LABORATORIES
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
DIVIS LABORATORIES
Mar-17
PANACEA BIOTECH/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1491,222 12.2%   
Low Rs82784 10.5%   
Sales per share (Unadj.) Rs84.1153.1 55.0%  
Earnings per share (Unadj.) Rs-18.339.9 -45.8%  
Cash flow per share (Unadj.) Rs-6.744.6 -15.0%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.0 0.0%  
Book value per share (Unadj.) Rs83.7201.8 41.5%  
Shares outstanding (eoy) m61.25265.47 23.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.46.6 21.0%   
Avg P/E ratio x-6.325.1 -25.1%  
P/CF ratio (eoy) x-17.222.5 -76.7%  
Price / Book Value ratio x1.45.0 27.8%  
Dividend payout %025.0 0.0%   
Avg Mkt Cap Rs m7,074266,266 2.7%   
No. of employees `0002.89.7 28.2%   
Total wages/salary Rs m1,4494,687 30.9%   
Avg. sales/employee Rs Th1,874.14,175.0 44.9%   
Avg. wages/employee Rs Th527.0481.5 109.4%   
Avg. net profit/employee Rs Th-407.71,089.3 -37.4%   
INCOME DATA
Net Sales Rs m5,15440,643 12.7%  
Other income Rs m100749 13.3%   
Total revenues Rs m5,25441,392 12.7%   
Gross profit Rs m-76614,460 -5.3%  
Depreciation Rs m7111,233 57.7%   
Interest Rs m1,50323 6,650.4%   
Profit before tax Rs m-2,88113,953 -20.6%   
Minority Interest Rs m110-   
Prior Period Items Rs m-60-   
Extraordinary Inc (Exp) Rs m1,7710-   
Tax Rs m173,349 0.5%   
Profit after tax Rs m-1,12110,604 -10.6%  
Gross profit margin %-14.935.6 -41.8%  
Effective tax rate %-0.624.0 -2.4%   
Net profit margin %-21.826.1 -83.4%  
BALANCE SHEET DATA
Current assets Rs m3,81040,105 9.5%   
Current liabilities Rs m8,3656,595 126.9%   
Net working cap to sales %-88.482.5 -107.2%  
Current ratio x0.56.1 7.5%  
Inventory Days Days156119 131.3%  
Debtors Days Days6781 83.3%  
Net fixed assets Rs m14,48019,995 72.4%   
Share capital Rs m61531 11.5%   
"Free" reserves Rs m90353,043 1.7%   
Net worth Rs m5,12753,574 9.6%   
Long term debt Rs m5,8320-   
Total assets Rs m19,43361,585 31.6%  
Interest coverage x-0.9618.4 -0.1%   
Debt to equity ratio x1.10-  
Sales to assets ratio x0.30.7 40.2%   
Return on assets %2.017.3 11.4%  
Return on equity %-21.919.8 -110.5%  
Return on capital %3.626.1 13.9%  
Exports to sales %24.50-   
Imports to sales %10.225.2 40.3%   
Exports (fob) Rs m1,264NA-   
Imports (cif) Rs m52510,259 5.1%   
Fx inflow Rs m1,53935,384 4.4%   
Fx outflow Rs m94210,399 9.1%   
Net fx Rs m59724,985 2.4%   
CASH FLOW
From Operations Rs m59911,493 5.2%  
From Investments Rs m-438-11,372 3.9%  
From Financial Activity Rs m-303-93 325.0%  
Net Cashflow Rs m-14128 -497.5%  

Share Holding

Indian Promoters % 74.5 52.0 143.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 11.8 5.1%  
FIIs % 1.3 19.0 6.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 17.2 137.2%  
Shareholders   10,259 31,796 32.3%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   DR. REDDYS LAB  STERLING BIOTECH  ASTRAZENECA PHARMA  AUROBINDO PHARMA  IPCA LABS  

Compare PANACEA BIOTECH With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Trade Flat; Realty Sector Down 2.1%(11:30 am)

Stock markets in India are presently trading on a flattish note. Sectoral indices are trading on a mixed note with stocks in the realty sector and metal sector witnessing maximum selling pressure.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Jan 16, 2018 12:45 PM

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH - GSK PHARMA COMPARISON

COMPARE PANACEA BIOTECH WITH

MARKET STATS